Form 4: Alkermes Director Shane Cooke Granted Significant Equity Awards

Alkermes plc Director Shane Cooke was granted 13,474 non-qualified stock options and 6,142 restricted stock units on May 21, 2025, as part of his compensation.

Summary

• Shane Cooke, a Director of Alkermes plc (ALKS), received equity awards on May 21, 2025.
• The awards include 13,474 non-qualified stock options with an exercise price of $30.53 per share.
• These stock options are set to vest in full on May 21, 2026, and will expire on May 21, 2035.
• Additionally, Mr. Cooke was granted 6,142 Restricted Stock Units (RSUs), with each unit representing a contingent right to receive one ordinary share.
• The Restricted Stock Units are also scheduled to vest in full on May 21, 2026.

Sentiment

Score: 7

Explanation: The filing indicates an insider receiving equity awards, which is generally a positive signal as it aligns the director's interests with shareholders and is a standard form of compensation, implying confidence in future performance. It's not a 'strong buy' signal as it's routine compensation, not a direct investment by the insider.

Positives

• The granting of equity awards to a director aligns management's interests with those of shareholders, as the value of these awards is directly tied to the company's stock performance.
• These awards represent a commitment to retaining key leadership within the company, fostering long-term stability and strategic continuity.

Future Outlook

The equity awards, with a vesting date in May 2026, are designed to incentivize the director to contribute to the company's long-term growth and share price appreciation, aligning future performance with compensation.

Industry Context

The granting of equity compensation, such as stock options and restricted stock units, is a standard practice in the pharmaceutical and biotechnology industries to attract, retain, and motivate executive talent and align their interests with shareholders.

Comparison to Industry Standards

• The use of non-qualified stock options and restricted stock units as part of executive compensation is a common practice across the pharmaceutical and biotech sectors.
• This compensation structure is comparable to those seen at major industry players like Biogen, Gilead Sciences, or Amgen, which frequently utilize similar equity-based incentives for their directors and executives to foster long-term value creation.

Stakeholder Impact

• Shareholders: The awards align the director's financial interests with shareholder value creation, potentially leading to more focused efforts on company performance and long-term growth.
• Employees: May signal stability in leadership and a standard, competitive approach to executive compensation within the company.

Next Steps

• The stock options and restricted stock units will vest on May 21, 2026, at which point the director will gain full ownership or exercisability of the shares, subject to the terms of the awards.

Key Dates

Recommendation

Keywords

Alkermes, ALKS, Shane Cooke, Director, Stock Option, Restricted Stock Unit, Equity Award, Insider Transaction, SEC Form 4, Beneficial Ownership